MINNEAPOLIS, April 9, 2018 /PRNewswire/ -- DaVita
Clinical Research (DCR), a specialty contract research organization
and subsidiary of DaVita Inc. (NYSE: DVA) with services spanning
the full spectrum of drug and device development, will present
three research abstracts from company representatives and
collaborators at the National Kidney Foundation's 2018 Spring
Clinical Meetings in Austin, Texas
April 10-14.
The Spring Clinical Meeting convenes roughly 3,000 health care
professionals to learn about the newest developments in nephrology
practice and present research findings.
"Sharing research and exchanging ideas at this conference helps
the entire kidney care community evolve and understand how we can
deliver even better patient care," said Steven Brunelli, M.D., MSCE, vice president and
medical director of health analytics for DCR.
Researchers from DCR and DaVita Kidney
Care will present results from several retrospective
studies. The data originates from DCR and its independent research
partners in the academic, pharmaceutical and biotech research
communities.
DCR poster titles include:
- Pharmacokinetics, Safety, and Tolerability of Thrice-Weekly
Dosing of Cinacalcet in Hemodialysis Patients with Secondary
Hyperparathyroidism
- Hospitalizations among Peritoneal Dialysis and Home
Hemodialysis Patients with Symptoms of Depression
- Characterization of End-Stage Renal Disease Patients on the
Transplant Waitlist
To learn more about DCR, visit
www.DaVitaClinicalResearch.com.
About DaVita Clinical Research
DaVita Clinical
Research (DCR), a wholly owned subsidiary of DaVita Inc., uses its
extensive, applied database and real-world healthcare experience to
assist pharmaceutical and medical device companies in the design,
recruitment and completion of retrospective, prospective and
pragmatic clinical trials. DCR's Late Phase Clinical Research
(Phase IIb through post-marketing) network of physicians and
investigative sites are focused on providing world-class research
in both complex/specialty populations and therapeutic areas and
especially in CKD and ESRD populations. To learn more about DCR,
visit DaVitaClinicalResearch.com.
About DaVita Inc.
DaVita Inc., a Fortune 500® company, is the parent company of
DaVita Kidney Care and DaVita
Medical Group. DaVita Kidney Care is
a leading provider of kidney care in the
United States, delivering dialysis services to patients with
chronic kidney failure and end stage renal disease. As of
Dec. 31, 2017, DaVita Kidney Care operated or provided
administrative services at 2,510 outpatient dialysis centers
located in the United States
serving approximately 198,000 patients. The company also operated
237 outpatient dialysis centers located in 11 countries outside
the United States. DaVita Medical
Group manages and operates medical groups and affiliated physician
networks in California,
Colorado, Florida, Nevada, New
Mexico, Pennsylvania and
Washington in its pursuit to
deliver excellent-quality health care in a dignified and
compassionate manner. DaVita Medical Group's teammates, employed
clinicians and affiliated clinicians provided care for
approximately 1.7 million patients. For more information, please
visit DaVita.com/About.
Contact Information
Media:
Ashley Henson
(303) 876-6626
Ashley.Henson@davita.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/national-kidney-foundation-features-davita-clinical-research-results-at-2018-spring-clinical-meetings-300626409.html
SOURCE DaVita Clinical Research